Cargando…
Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
BACKGROUND: Accurate response parameters are important for patients with brain metastasis (BM) undergoing clinical trials using immunotherapy, considering poorly defined enhancement and variable responses. This study investigated MRI-based surrogate endpoints for patients with BM receiving immunothe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594817/ https://www.ncbi.nlm.nih.gov/pubmed/37875970 http://dx.doi.org/10.1186/s40644-023-00624-0 |
_version_ | 1785124731280687104 |
---|---|
author | Roh, Yun Hwa Park, Ji Eun Kang, Sora Yoon, Shinkyo Kim, Sang-We Kim, Ho Sung |
author_facet | Roh, Yun Hwa Park, Ji Eun Kang, Sora Yoon, Shinkyo Kim, Sang-We Kim, Ho Sung |
author_sort | Roh, Yun Hwa |
collection | PubMed |
description | BACKGROUND: Accurate response parameters are important for patients with brain metastasis (BM) undergoing clinical trials using immunotherapy, considering poorly defined enhancement and variable responses. This study investigated MRI-based surrogate endpoints for patients with BM receiving immunotherapy. METHODS: Sixty-three non-small cell lung cancer patients with BM who received immune checkpoint inhibitors and underwent MRI were included. Tumor diameters were measured using a modification of the RECIST 1.1 (mRECIST), RANO-BM, and iRANO adjusted for BM (iRANO-BM). Tumor volumes were segmented on 3D contrast-enhanced T1-weighted imaging. Differences between the sum of the longest diameter (SLD) or total tumor volume at baseline and the corresponding measurement at time of the best overall response were calculated as “changes in SLDs” (for each set of criteria) and “change in volumetry,” respectively. Overall response rate (ORR), progressive disease (PD) assignment, and progression-free survival (PFS) were compared among the criteria. The prediction of overall survival (OS) was compared between diameter-based and volumetric change using Cox proportional hazards regression analysis. RESULTS: The mRECIST showed higher ORR (30.1% vs. both 17.5%) and PD assignment (34.9% vs. 25.4% [RANO-BM] and 19% [iRANO-BM]). The iRANO-BM had a longer median PFS (13.7 months) than RANO-BM (9.53 months) and mRECIST (7.73 months, P = 0.003). The change in volumetry was a significant predictor of OS (HR = 5.87, 95% CI: 1.46–23.64, P = 0.013). None of the changes in SLDs, as determined by RANO-BM or iRANO-BM, were significant predictors of OS, except for the mRECIST, which exhibited a weak association with OS. CONCLUSION: Quantitative volume measurement may be an accurate surrogate endpoint for OS in patients with BM undergoing immunotherapy, especially considering the challenges of multiplicity and the heterogeneity of sub-centimeter size responses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00624-0. |
format | Online Article Text |
id | pubmed-10594817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105948172023-10-25 Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria Roh, Yun Hwa Park, Ji Eun Kang, Sora Yoon, Shinkyo Kim, Sang-We Kim, Ho Sung Cancer Imaging Research Article BACKGROUND: Accurate response parameters are important for patients with brain metastasis (BM) undergoing clinical trials using immunotherapy, considering poorly defined enhancement and variable responses. This study investigated MRI-based surrogate endpoints for patients with BM receiving immunotherapy. METHODS: Sixty-three non-small cell lung cancer patients with BM who received immune checkpoint inhibitors and underwent MRI were included. Tumor diameters were measured using a modification of the RECIST 1.1 (mRECIST), RANO-BM, and iRANO adjusted for BM (iRANO-BM). Tumor volumes were segmented on 3D contrast-enhanced T1-weighted imaging. Differences between the sum of the longest diameter (SLD) or total tumor volume at baseline and the corresponding measurement at time of the best overall response were calculated as “changes in SLDs” (for each set of criteria) and “change in volumetry,” respectively. Overall response rate (ORR), progressive disease (PD) assignment, and progression-free survival (PFS) were compared among the criteria. The prediction of overall survival (OS) was compared between diameter-based and volumetric change using Cox proportional hazards regression analysis. RESULTS: The mRECIST showed higher ORR (30.1% vs. both 17.5%) and PD assignment (34.9% vs. 25.4% [RANO-BM] and 19% [iRANO-BM]). The iRANO-BM had a longer median PFS (13.7 months) than RANO-BM (9.53 months) and mRECIST (7.73 months, P = 0.003). The change in volumetry was a significant predictor of OS (HR = 5.87, 95% CI: 1.46–23.64, P = 0.013). None of the changes in SLDs, as determined by RANO-BM or iRANO-BM, were significant predictors of OS, except for the mRECIST, which exhibited a weak association with OS. CONCLUSION: Quantitative volume measurement may be an accurate surrogate endpoint for OS in patients with BM undergoing immunotherapy, especially considering the challenges of multiplicity and the heterogeneity of sub-centimeter size responses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00624-0. BioMed Central 2023-10-24 /pmc/articles/PMC10594817/ /pubmed/37875970 http://dx.doi.org/10.1186/s40644-023-00624-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Roh, Yun Hwa Park, Ji Eun Kang, Sora Yoon, Shinkyo Kim, Sang-We Kim, Ho Sung Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria |
title | Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria |
title_full | Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria |
title_fullStr | Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria |
title_full_unstemmed | Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria |
title_short | Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria |
title_sort | prognostic value of mri volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594817/ https://www.ncbi.nlm.nih.gov/pubmed/37875970 http://dx.doi.org/10.1186/s40644-023-00624-0 |
work_keys_str_mv | AT rohyunhwa prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria AT parkjieun prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria AT kangsora prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria AT yoonshinkyo prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria AT kimsangwe prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria AT kimhosung prognosticvalueofmrivolumetricparametersinnonsmallcelllungcancerpatientsafterimmunecheckpointinhibitortherapycomparisonwithresponseassessmentcriteria |